INNOVATION UK HEALTHCARE More recently, the WIBGI ap-proach was applied to the DH's Healthcare Acquired Infection programme ( HCAI). With HCAIs costing the NHS over £ 1 billion a year, the ' needs based' approach again brought the NHS, industry and design experts together to look at cross- infection issues and jointly develop solutions. Based on an ' open innovation' model, the approach overcame tradi-tional barriers by working more closely with industry and directly linking health need to technology supply. The aim was to get prod-ucts designed, developed and in place so that they could benefit patients as quickly as possible. The result was 17 new product designs in as many months - a significantly faster solution than the traditional approach of wait-ing for the market to develop new products and then procure and implement them. Open Innovation platforms The NIC is currently using its novel approach in six other ar-eas - Blood Donation, Paediatrics, Urology, Ambulance Services, Heart Failure and Regenerative Medicine. Again working in part-nership with the TSB, the NIC brought together clinical teams from each of the disciplines to first identify the needs. At sub-sequent meetings, NHS, industry and academia came together to outline the desired solutions, the business opportunities they might present and other requirements that might be needed to bring the concept to market. By using an ' open innovation' approach, the silos that are usually created around IP ownership, product de-velopment and procurement were avoided and all parties were able to focus their efforts on the out-come required. Managing the growth of the solution All of the WIBGI outcomes are now posted on the NIC website http:// competitions. nic. nhs. uk/ ChallengeList. aspx so that exter-nal suppliers can apply to address the needs. The NIC expects that some of the solutions will be met by industry with minimum input; others will demand more support from the NIC who will work with external suppliers to develop so-lutions to the articulated needs. NIC will provide financial support to help commercial companies either develop ideas unilaterally or in collaboration with others. This is a structured process that involves the NIC liaising along the way with the NHS Supply Chain to support ultimately the take- up of the products across the NHS. A temporary isolation unit and improved handwashing procedures were amongst 17 ideas that are in development to control the spread of Healthcare Acquired Infections. Clinicians, academics, industrialists and designers from across the innovation spectrum came together at the WIBGI innovation work-shops at ExCel in June to outline solutions to clinically identified need. The NIC will now take a dozen ideas forward for further de-velopment.
HEALTHCARENational Innovation Centre www. nic. nhs. uk Case study - prostate cancer - the WIBGI approach In summer 2009, the British Urological Insti-tute and the Devices for Dignity HTC identified a number of important clinical needs within the Urology service. They said: " Wouldn't It Be Great If. we had improved biopsy analysis for suspected prostate cancer cases". The organi-sations also suggested desired solutions, the business opportunities they might present and other requirements that might be needed to bring the concept to market. Here's what they said about the need: . PSA tests have led to a large increase in sus-pected cases of prostate cancer requiring an invasive biopsy of the prostrate. . The biopsy of the prostrate requires samples taken from multiple sites to ensure a rep-resentative tissue sampling, it is inaccurate and unpleasant for the patient and has sig-nificant complications. . In around 70% of cases, the biopsy process does not reveal a clinically significant pros-tate cancer which requires further surgical intervention. Here's what they said about desired solution attributes: The main features should be: . Improved ergonomics for patient and surgeon; . Design to allow multi- site testing from single insertion; . Less painful for the patient; . A ' one- click' test; . New access route; . Metrics to identify aggressive cancer; . Less pain through local anaesthetics; . Less pain through ' micro- needles'; . Combine diagnostic with therapy; . Improved needle guidance; . Visualisation of prostate; . Less post- op bleeding; . Infra- red tissue imaging from rectum; . Contrast imaging for prostate; . Contrast that sticks to PSA; . Improved biopsy analysis to avoid need for cone biopsy; . Improved needle design ( to avoid needle stick risk); . Acceptable cost to Trust. Here's what they said about business opportunities: . Men live longer lives; . Read across to/ from other procedures; . 50% of world's population as potential patients; . Market size to make business case; . No other solution imminent so wide window of opportunity; . Global market size; . Other solid organ cancers; . Reduce cost to NHS; . Cost to develop technology; . Risk: NHS not accepting the benefits; . Disposable commodities: business opportunities for service; . What is the purchaser's view and tariff; . Screening entire population will follow if prognostic tests are effective; . Other cancer biopsy opportunities; . Cannot understand market failure; . IP; . Four/ five different technologies need to come together; . Pharmaceutical solution would make device approach redundant. Here's what they said about research requirements: . Gather stats on outcomes of current surgical procedures; . Health economic questions; . How men die of prostate cancer after a reassuring biopsy result; . What percentage of cancers are aggressive; . Is oral/ local pain therapy of any value; . Is workflow optimised; . Isolating/ storing tissue for research; . Industry interest; . How to improve prostate contrast; . How many cancers are upgraded or downgraded by full prostatectomy; . Review surgical environment to be more procedure friendly; . Proper evaluation of disruptive technologies; . How many refuse biopsy because it is so awful; . Pain management: before, during, after . Idealised theatre layout; . Cost of ' missing' in first biopsy- CT; . Market drivers minimum sample size for validity; . Research technologies used in other areas ( endoscopy etc); . What is approach in US/ Japan; . Understanding risk factors, genetics, lifestyle, hormonal effects. Here's what they said about enablers: . Seed funding ( e. g. for improved tool design); . Public health awareness of prostate cancer . Cool technology ( e. g. Da Vinci machine); . Better treatment outcomes; . NHS approved; . Articles in lay press; . Pressure groups; . Competition incentive for industry to get involved. For further information and application forms, see: http:// competitions. nic. nhs. uk/ ChallengeList. aspx Urology needs Non- intrusive rapid diagnosis Clinicians attending a Urology WIBGI said that there was a priority need for accurate, non-intrusive rapid diagnosis of prostate cancer